GlassScriptPhysician profile
Robert K Luntz
NPI 1609869361
$3,733.68
in general payments reported to CMS, 2019-2025
25 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $191 · 2021: $540 · 2022: $570 · 2023: $978 · 2024: $636 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.68 |
| Education | $135.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $794.51 | 2020-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $483.80 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $370.07 | 2020-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $286.46 | 2022-2025 | |
| Procept Biorobotics Corporation | $243.87 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $221.73 | 2020-2024 | Xtandi, Myrbetriq |
| Neotract INC. | $212.76 | 2019-2020 | |
| Myovant Sciences INC. | $175.44 | 2021-2022 | |
| Pfizer INC. | $151.55 | 2021-2025 | |
| Teleflex LLC | $125.86 | 2021-2025 | Urolift |
| Urovant Sciences INC | $90.55 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $85.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.44 | 2022-2023 | Welireg, Keytruda, Lynparza |
| Coloplast Corp | $60.00 | 2021-2022 | |
| Tolmar, INC. | $59.24 | 2024-2025 | Eligard |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $46.57 | 2021 | |
| Endo USA, INC. | $44.06 | 2025 | Aveed, Xiaflex |
| Amgen INC. | $37.97 | 2022-2023 | Xgeva |
| Accord Healthcare, INC. | $36.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $26.30 | 2023 | Pylarify |
| Myriad Genetic Laboratories, INC. | $23.94 | 2023 | Prolaris |
| Abbvie INC. | $21.98 | 2022 | |
| Rochester Medical Corporation | $20.45 | 2020 | |
| Boston Scientific Corporation | $18.31 | 2024 | Greenlight Xps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Luntz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.